REVIEW
Receptor-activated SMAD and receptor degradation is promoted by E3 ubiquitin ligases such as SMAD ubiquitination regulatory factor 1 (SMURF1). 1 The transcriptional regulation ability of SMADs can be blocked by interaction with inhibitory proteins such as ski-related novel protein N (SnoN).
Antagonism Between BMP and Activin/TGF-β Signaling
Genomic and genetic studies have revealed that the same basic pathway architecture found in humans is conserved among all other animals. Two distinct signaling pathways are located downstream of the TGF-β superfamily ligands (Table) . In general, structural considerations delineate the TGF-β superfamily into ligands that interact with ALK1/2/3/6 or ALK4/5/7, the former being mostly BMPs (some of which are also called GDFs) and the latter being mostly activins and TGF-βs. Evolutionarily, it is likely that the BMP response (activation of RA-SMADs 1, 5, and 8) is ancestral, whereas the activin/TGF-β response (activation of RA-SMADs 2 and 3) arose later. 1 However, both pathways converge at the common transcription factor SMAD4, which helps explain the synergistic effects that are often observed upon combined activation.
On the other hand, reports of markedly opposing effects between the BMP and activin/TGF-β pathways are becoming increasingly common, especially in disease states, with more than 50 articles published in the 
TGF-β Superfamily Signaling Pathway
In humans, the TGF-β superfamily consists of more 
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Clinical and Physiologic Contexts of Antagonism
Musculoskeletal System
Osteoporosis affects 10 million people in the United
States and accounts for 1.5 million fractures annually. 5, 6 With an additional 34 million people in the United States at risk for the disease, osteoporosis is both a major health problem and a considerable socioeconomic burden. 
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Antagonistic Mechanisms
Collectively, the studies cited above indicate that antagonism between these pathways occurs in varied cellular and physiologic contexts, many of which are clinically relevant. It should also be noted that the antagonistic relationship operates bidirectionally and in response to numerous ligands. We contend that a better understanding of the molecular mechanisms mediating the interaction between these signaling pathways may identify novel strategies for therapeutic intervention. And, antagonism between these pathways can be observed at the level of RA-SMAD activation, 35 which is both independent and upstream of SMAD4 recruitment;
in other words, the tug of war game can be influenced before anyone gets to the rope in the first place.
We do not favor the idea that differential gene ex- 
